ArticleFrontiers in immunology2026
Polyfunctional antibody signature defines protection in Andes hantavirus survival.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Andes orthohantavirus (ANDV) is a deadly pathogen that causes hantavirus cardiopulmonary syndrome (HCPS), which is a severe disease characterized by respiratory failure and high mortality rates (~30-40%). While previous studies have shown that neutralizing antibodies have a critical role in survival, the contribution of the Fc-mediated effector functions remains unexplored. Methods: We performed a serological profiling of acute HCPS patients and survivors, analyzing antibody types, subtypes, and neutralization capacity targeting ANDV glycoproteins (Gn and GnGc). Fc-mediated effector functions, which are key to defining antibody-mediated correlates of protection, were analyzed using FcγR reporter signaling assays, antibody-dependent NK cell activation, and antibody-dependent complement deposition (ADCD). Results: Acute HCPS patients who developed moderate disease exhibited significantly higher IgG levels against the Gn glycoprotein and stronger Fc-mediated effector functions, including antibody-dependent NK cell activation and ADCD against glycoproteins, compared to the more severe cases. Surviving acute patients showed elevated IgG and IgM responses against Gn. In survivors, polyfunctional non-neutralizing IgG activities persisted for years after infection and were more pronounced against the GnGc complex than Gn alone. Conclusion: In summary, our study reveals the existence of functional diversity in the humoral immune response to ANDV glycoprotein during HCPS, which can be associated with protective responses and may contribute to a long-lasting immune response to restrict ANDV infection. These findings identify Fc effector functions as important correlates of protection and provide valuable insights for the design of next-generation vaccines and therapeutics against hantaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.